A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
Study Purpose
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years - 99 Years |
| Gender | All |
Inclusion Criteria:
1. Signed informed consent form and assent form, as appropriate. 2. Male or female ≥12 years of age at Screening Visit 1. Sites in Poland will only include participants aged ≥18 years. Asthma-related criteria. 3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1. 4. Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting β2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Note: In Poland, this will instead include participants requiring a minimum daily medium dose ICS (≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021). Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1. 5. Pre-BD FEV1 ≥40% and <80% (<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2. 6. Bronchodilator reversibility, at Screening Visit 2, as evidenced by ≥12% and ≥200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17).Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening Period, at an unscheduled visit at least 7 days prior to baseline. 7. ACQ-6 ≥1.5 at Screening Visit 2. 8. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2). General medical history. 9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits. 10. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit: 1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive. Or. 2. Two protocol acceptable methods of contraception in tandem.- - Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.
Exclusion Criteria:
Asthma-related criteria. 1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization prior to the Screening Visit 1 up to and including the Baseline Visit. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status. 2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, or hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis). 3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1. Prohibited medications/procedures. 4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long acting anti-interleukin-5) in the past 12 months. 5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. 6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline. 7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1. 8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the study period. General medical history. 9. Weight <40 kg at Screening Visit 2. 10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of >10 packyears. Smoking includes tobacco, vaping, and/or marijuana use. 11. Known or suspected alcohol or drug abuse. 12. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to the Baseline Visit despite antihypertensive therapy. 13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to the Baseline Visit. 14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C. 15. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1, that has not been treated with or has failed to respond to standard of care therapy. 16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements. 17. Known or suspected noncompliance with medication. 18. Unwillingness or inability to follow the procedures outlined in the protocol. Clinical safety labs. 19. Absolute neutrophil count <2.000x10⁹/L at Screening Visit 1 or Screening Visit 2.. 20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [Levey et al, 2009] for age ≥18 years at screening; using the Bedside Schwartz [Schwartz and Work, 2009] eGFR formula for age <18). 21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. Cardiac safety. 22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction <25%. 23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit. 24. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation. 25. History of long QT syndrome. 26. Corrected QT interval by Fridericia (QTcF) interval >450 ms for males and >470 ms for females at Screening Visit 2 or QTcF ≥480 ms for participants with bundle branch block. 27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including resting heart rate <45 beats per minute (bpm) or >100 bpm. Pregnancy/Lactation. 28. Pregnant women or women breastfeeding. 29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide). For this study, rescreening may only be permitted under specific circumstances and only after contact with a Sponsor Clinical representative.Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05748600 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Areteia Therapeutics |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Mona Bafadhel, MD |
| Principal Investigator Affiliation | Guy's and St Thomas' NHS Foundation Trust |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Argentina, Austria, Brazil, Canada, Israel, Malaysia, Mexico, Poland, Puerto Rico, Romania, South Africa, South Korea, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack |
Arms
Experimental: 150 mg BID
Dexpramipexole 150 mg oral tablet taken twice a day
Experimental: 75 mg BID
Dexpramipexole 75 mg oral tablet taken twice a day
Placebo Comparator: Placebo
Placebo oral tablet taken twice a day
Interventions
Drug: - Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet
Drug: - Placebo
administration of placebo tablet
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Research Site 40001-487
Chandler 5289282, Arizona 5551752, 85224
Status
Address
Research Site 40001-462
Peoria 5308480, Arizona 5551752, 85381
Status
Address
Research Site 40001-322
Surprise 5316428, Arizona 5551752, 85378
Status
Address
Research Site 40001-374
Bakersfield 5325738, California 5332921, 93301
Status
Address
Research Site 40001-227
Encinitas 5346646, California 5332921, 92024
Status
Address
Research Site 40001-349
Huntington Beach 5358705, California 5332921, 92647
Status
Address
Research Site 40001-485
Inglewood 5359488, California 5332921, 06410
Status
Address
Research Site 40001-440
La Palma 5364022, California 5332921, 90623
Status
Address
Research Site 40001-357
Lancaster 5364940, California 5332921, 93534
Status
Address
Research Site 40001-089
Los Angeles 5368361, California 5332921, 90048
Status
Address
Research Site 40001-362
Mission Viejo 5373763, California 5332921, 92691
Status
Address
Research Site 40001-449
Napa 5376095, California 5332921, 94558
Status
Address
Research Site 40001-062
Newport Beach 5376890, California 5332921, 92660
Status
Address
Research Site 40001-043
Newport Beach 5376890, California 5332921, 92663
Status
Address
Research Site 40001-380
Redding 5570160, California 5332921, 96001
Status
Address
Research Site 40001-434
San Diego 5391811, California 5332921, 92123
Status
Address
Research Site 40001-088
San Jose 5392171, California 5332921, 95117
Status
Address
Research Site 40001-359
Upland 5404915, California 5332921, 91756
Status
Address
Research Site 40001-003
West Covina 5407933, California 5332921, 91790
Status
Address
Research Site 40001-419
Westminster 5408406, California 5332921, 92683
Status
Address
Research Site 40001-425
Aurora 5412347, Colorado 5417618, 80014
Status
Address
Research Site 40001-353
Colorado Springs 5417598, Colorado 5417618, 80907
Status
Address
Research Site 40001-385
Wheat Ridge 5443948, Colorado 5417618, 80033
Status
Address
Research Site 40001-048
Aventura 4146429, Florida 4155751, 33180
Status
Address
Research Site 40001-005
Brandon 4148757, Florida 4155751, 33511
Status
Address
Research Site 40001-051
Brandon 4148757, Florida 4155751, 33511
Status
Address
Research Site 40001-029
Coral Gables 4151871, Florida 4155751, 33134
Status
Address
Research Site 40001-350
Gainesville 4156404, Florida 4155751, 32607
Status
Address
Research Site 40001-014
Greenacres City 4157467, Florida 4155751, 33467
Status
Address
Research Site 40001-054
Hialeah 4158476, Florida 4155751, 33012
Status
Address
Research Site 40001-067
Hialeah 4158476, Florida 4155751, 33016
Status
Address
Research Site 40001-020
Homestead 4159050, Florida 4155751, 33030
Status
Address
Research Site 40001-015
Kissimmee 4160983, Florida 4155751, 34744
Status
Address
Research Site 40001-002
Kissimmee 4160983, Florida 4155751, 34746
Status
Address
Research Site 40001-086
Loxahatchee Groves 4162948, Florida 4155751, 33470
Status
Address
Research Site 40001-318
Maitland 4163220, Florida 4155751, 32751
Status
Address
Research Site 40001-066
Miami 4164138, Florida 4155751, 33126
Status
Address
Research Site 40001-001
Miami 4164138, Florida 4155751, 33135
Status
Address
Research Site 40001-059
Miami 4164138, Florida 4155751, 33144
Status
Address
Research Site 40001-026
Miami 4164138, Florida 4155751, 33155
Status
Address
Research Site 40001-288
Miami 4164138, Florida 4155751, 33165
Status
Address
Research Site 40001-065
Miami 4164138, Florida 4155751, 33173
Status
Address
Research Site 40001-024
Miami 4164138, Florida 4155751, 33184
Status
Address
Research Site 40001-338
Miami Beach 4164143, Florida 4155751, 33169
Status
Address
Research Site 40001-348
Ocala 4166673, Florida 4155751, 34471
Status
Address
Research Site 40001-293
Orlando 4167147, Florida 4155751, 32819
Status
Address
Research Site 40001-429
Plantation 4168782, Florida 4155751, 33317
Status
Address
Research Site 40001-351
Sarasota 4172131, Florida 4155751, 34239
Status
Address
Research Site 40001-069
St. Petersburg 4171563, Florida 4155751, 33713
Status
Address
Research Site 40001-370
Tallahassee 4174715, Florida 4155751, 32308
Status
Address
Research Site 40001-004
Tampa 4174757, Florida 4155751, 33607
Status
Address
Research Site 40001-319
Viera 4176456, Florida 4155751, 32940
Status
Address
Research Site 40001-142
Adairsville 4179094, Georgia 4197000, 30103
Status
Address
Research Site 40001-075
Augusta 4180531, Georgia 4197000, 30909
Status
Address
Research Site 40001-018
Columbus 4188985, Georgia 4197000, 31904
Status
Address
Research Site 40001-452
Dunwoody 4192375, Georgia 4197000, 30350
Status
Address
Research Site 40001-483
East Point 4192674, Georgia 4197000, 30344
Status
Address
Research Site 40001-366
Lilburn 4205724, Georgia 4197000, 30047
Status
Address
Research Site 40001-423
Savannah 4221552, Georgia 4197000, 31406
Status
Address
Research Site 40001-090
Berwyn 4884597, Illinois 4896861, 60402
Status
Address
Research Site 40001-343
Chicago 4887398, Illinois 4896861, 60607
Status
Address
Research Site 40001-358
Normal 4903780, Illinois 4896861, 61761
Status
Address
Research Site 40001-135
River Forest 4907637, Illinois 4896861, 60305
Status
Address
Research Site 40001-403
Skokie 4911600, Illinois 4896861, 60077
Status
Address
Research Site 40001-036
Elwood 4920041, Indiana 4921868, 46036
Status
Address
Research Site 40001-347
Louisville 4299276, Kentucky 6254925, 40202
Status
Address
Research Site 40001-019
Owensboro 4303436, Kentucky 6254925, 42301
Status
Address
Research Site 40001-437
Alexandria 4314550, Louisiana 4331987, 71303
Status
Address
Research Site 40001-313
Marrero 4332628, Louisiana 4331987, 70072
Status
Address
Research Site 40001-352
Zachary 4346788, Louisiana 4331987, 70791
Status
Address
Research Site 40001-417
Annapolis 4347242, Maryland 4361885, 21401
Status
Address
Research Site 40001-466
Baltimore 4347778, Maryland 4361885, 21237
Status
Address
Research Site 40001-456
Takoma Park 4370890, Maryland 4361885, 20912
Status
Address
Research Site 40001-055
White Marsh 4373426, Maryland 4361885, 21162
Status
Address
Research Site 40001-468
Fall River 4936159, Massachusetts 6254926, 02723
Status
Address
Research Site 40001-427
Dearborn 4990510, Michigan 5001836, 48126
Status
Address
Research Site 40001-006
Flint 4992982, Michigan 5001836, 48504
Status
Address
Research Site 40001-148
Flint 4992982, Michigan 5001836, 48507
Status
Address
Research Site 40001-463
Rochester Hills 5007402, Michigan 5001836, 48307
Status
Address
Research Site 40001-442
Southfield 5010636, Michigan 5001836, 48034
Status
Address
Research Site 40001-372
Warren 5014051, Michigan 5001836, 48088
Status
Address
Research Site 40001-421
Mankato 5036420, Minnesota 5037779, 56001
Status
Address
Research Site 40001-083
Columbia 4381982, Missouri 4398678, 65203
Status
Address
Research Site 40001-074
Saint Charles 4406831, Missouri 4398678, 63301
Status
Address
Research Site 40001-046
St Louis 4407066, Missouri 4398678, 63110
Status
Address
Research Site 40001-409
Missoula 5666639, Montana 5667009, 59808
Status
Address
Research Site 40001-448
Lincoln 5072006, Nebraska 5073708, 68510
Status
Address
Research Site 40001-404
Omaha 5074472, Nebraska 5073708, 68798
Status
Address
Research Site 40001-473
Las Vegas 5506956, Nevada 5509151, 89109
Status
Address
Research Site 40001-387
Brick 5095947, New Jersey 5101760, 08724
Status
Address
Research Site 40001-363
Edison 5097529, New Jersey 5101760, 08817
Status
Address
Research Site 40001-457
Jersey City 5099836, New Jersey 5101760, 07304
Status
Address
Research Site 40001-355
Toms River 4504476, New Jersey 5101760, 08755
Status
Address
Research Site 40001-050
East Amherst 5115699, New York 5128638, 14051
Status
Address
Research Site 40001-412
Great Neck 5119218, New York 5128638, 11021
Status
Address
Research Site 40001-047
Hawthorne 5120284, New York 5128638, 10532
Status
Address
Research Site 40001-455
New York 5128581, New York 5128638, 10016
Status
Address
Research Site 40001-369
New York 5128581, New York 5128638, 10029
Status
Address
Research Site 40001-408
Charlotte 4460243, North Carolina 4482348, 28273
Status
Address
Research Site 40001-398
Charlotte 4460243, North Carolina 4482348, 28277
Status
Address
Research Site 40001-039
Gastonia 4467732, North Carolina 4482348, 28054
Status
Address
Research Site 40001-435
Greenville 4469160, North Carolina 4482348, 17834
Status
Address
Research Site 40001-111
Huntersville 4472370, North Carolina 4482348, 28078
Status
Address
Research Site 40001-382
Raleigh 4487042, North Carolina 4482348, 27610
Status
Address
Research Site 40001-439
Rocky Mount 4488762, North Carolina 4482348, 27804
Status
Address
Research Site 40001-283
Winston-Salem 4499612, North Carolina 4482348, 21704
Status
Address
Research Site 40001-034
Cincinnati 4508722, Ohio 5165418, 45215
Status
Address
Research Site 40001-013
Cincinnati 4508722, Ohio 5165418, 45219
Status
Address
Research Site 40001-010
Cincinnati 4508722, Ohio 5165418, 45236
Status
Address
Research Site 40001-413
Cleveland 5150529, Ohio 5165418, 44106
Status
Address
Research Site 40001-017
Dayton 4509884, Ohio 5165418, 45424
Status
Address
Research Site 40001-063
Toledo 5174035, Ohio 5165418, 43617
Status
Address
Research Site US-40001-038
Edmond 4535740, Oklahoma 4544379, 73034
Status
Address
Research Site 40001-386
Oklahoma City 4544349, Oklahoma 4544379, 73102
Status
Address
Research Site 40001-079
Oklahoma City 4544349, Oklahoma 4544379, 73120
Status
Address
Research Site 40001-027
Grants Pass 5729080, Oregon 5744337, 97527
Status
Address
Research Site 40001-337
Portland 5746545, Oregon 5744337, 97202
Status
Address
Research Site 40001-395
Hershey 5193342, Pennsylvania 6254927, 17033
Status
Address
Research Site 40001-327
Philadelphia 4560349, Pennsylvania 6254927, 19140
Status
Address
Research Site 40001-032
Columbia 4575352, South Carolina 4597040, 29204
Status
Address
Research Site 40001-025
Greenville 4580543, South Carolina 4597040, 29651
Status
Address
Research Site 40001-430
Rock Hill 4593142, South Carolina 4597040, 29732
Status
Address
Research Site 40001-073
Spartanburg 4597200, South Carolina 4597040, 29303
Status
Address
Research Site 40001-438
Dickson 4618057, Tennessee 4662168, 37055
Status
Address
Research Site 40001-414
Franklin 4623560, Tennessee 4662168, 37067
Status
Address
Research Site 40001-334
Allen 4670300, Texas 4736286, 75013
Status
Address
Research Site 40001-068
Amarillo 5516233, Texas 4736286, 79124
Status
Address
Research Site 40001-023
Dallas 4684888, Texas 4736286, 75230
Status
Address
Research Site 40001-028
Dallas 4684888, Texas 4736286, 75235
Status
Address
Research Site 40001-415
Dallas 4684888, Texas 4736286, 75246
Status
Address
Research Site 40001-304
DeSoto 4685524, Texas 4736286, 75115
Status
Address
Research Site 40001-418
Frisco 4692559, Texas 4736286, 75034
Status
Address
Research Site 40001-064
Houston 4699066, Texas 4736286, 77074
Status
Address
Research Site 40001-085
Houston 4699066, Texas 4736286, 77099
Status
Address
Research Site 40001-424
Kerrville 4703078, Texas 4736286, 78028
Status
Address
Research Site 40001-295
McKinney 4710178, Texas 4736286, 75069
Status
Address
Research Site 40001-304
Red Oak 4721921, Texas 4736286, 75154
Status
Address
Research Site 40001-377
San Antonio 4726206, Texas 4736286, 78258
Status
Address
Research Site 40001-335
Sugar Land 4734825, Texas 4736286, 77479
Status
Address
Research Site 40001-258
Murray 5778755, Utah 5549030, 84107
Status
Address
Research Site 40001-333
Pleasant View 5779833, Utah 5549030, 84404
Status
Address
Research Site 40001-340
Burke 4749950, Virginia 6254928, 22015
Status
Address
Research Site 40001-394
Williamsburg 4793846, Virginia 6254928, 23188
Status
Address
Research Site 40001-339
Greenfield 5255068, Wisconsin 5279468, 53228
Status
Address
Research Site 40001-433
La Crosse 5258957, Wisconsin 5279468, 54601
Status
Address
Research Site 40001-443
La Crosse 5258957, Wisconsin 5279468, 54601
International Sites
Status
Address
Research Site 40054-035
Buenos Aires 3435910, , B1878FNR
Status
Address
Research Site 40054-044
Buenos Aires 3435910, , B1878FNR
Status
Address
Research Site 40054-034
Buenos Aires 3435910, , B8000JRB
Status
Address
Research Site 40054-017
Buenos Aires 3435910, , C1027AAP
Status
Address
Research Site 40054-008
Buenos Aires 3435910, , C1426ABP
Status
Address
Research Site 40054-043
Buenos Aires 3435910, , C14426ABP
Status
Address
Research Site 40054-015
Caba, , C1121ABE
Status
Address
Research Site 40054-019
Mendoza 3844421, , M5500AXR
Status
Address
Research Site 40054-016
Mendoza 3844421, , M5500CBA
Status
Address
Research Site 40054-010
Mendoza 3844421, , M5500CCG
Status
Address
Research Site 40054-028
Mendoza 3844421, , M5501AAJ
Status
Address
Research Site 40054-032
Mendoza 3844421, , M5501GCA
Status
Address
Research Site 40054-057
Mendoza 3844421, , M5506BBH
Status
Address
Research Site 40054-024
San Miguel de Tucumán 3836873, , C1425BEN
Status
Address
Research Site 40054-002
San Miguel de Tucumán 3836873, , T4000CBC
Status
Address
Research Site 40054-020
San Miguel de Tucumán 3836873, , T4000IAJ
Status
Address
Research Site 30043-013
Salzburg 2766824, , 5020
Status
Address
Research Site 40055-015
Belo Horizonte 3470127, ,
Status
Address
Research Site 40055-007
Blumenau 3469968, , 89030-101
Status
Address
Research Site 40055-011
Campo Largo 3467736, , 83606-177
Status
Address
Research Site 40055-043
Curitiba 3464975, , 80060-900
Status
Address
Research Site 40055-036
Curitiba 3464975, , 80810-100
Status
Address
Research Site 40055-012
Porto Alegre 3452925, , 90035-074
Status
Address
Research Site 40055-004
Porto Alegre 3452925, , 90610-000
Status
Address
Research Site 40055-010
Porto Alegre 3452925, , 91010-006
Status
Address
Research Site 40055-035
Rio de Janeiro 3451190, , 22061-080
Status
Address
Research Site 40055-025
Salvador 3450554, , 40060-325
Status
Address
Research Site 40055-005
Santo André 3449701, , 09060-870
Status
Address
Research Site 40055-009
Santos 3449433, , 11075-900
Status
Address
Research Site 40055-001
São Bernardo do Campo 3449344, , 09715-090
Status
Address
Research Site 40011-004
Ajax 5882873, Ontario 6093943, L1S 2J5
Status
Address
Research Site 40011-016
Ajax 5882873, Ontario 6093943, L1Z 0M1
Status
Address
Research Site 40011-010
Burlington 5911592, Ontario 6093943, L7N
Status
Address
Research Site 40011-014
Ottawa 6094817, Ontario 6093943, K1H 1E4
Status
Address
Research Site 40011-005
Windsor 6182962, Ontario 6093943, N8X 2G1
Status
Address
Research Site 40011-001
Windsor 6182962, Ontario 6093943, N8X 5A6
Status
Address
Research Site 40011-018
Montreal 6077243, Quebec 6115047, H4A 3J1
Status
Address
Research Site 40011-022
Québec 6325494, Quebec 6115047, G1G 3Y8
Status
Address
Research Site 40011-020
Trois-Rivières 6169141, Quebec 6115047, G9A 4P3
Status
Address
Research Site 40011-011
Vancouver 6173331, , V5Z 1M9
Status
Address
Research Site 40972-010
Ashkelon 295620, , 7830604
Status
Address
Research Site 40972-008
Beersheba 295530, , 8410101
Status
Address
Research Site 40972-005
Haifa 294801, , 3109601
Status
Address
Research Site 40972-004
Haifa 294801, , 3436212
Status
Address
Research Site 40972-001
Jerusalem 281184, ,
Status
Address
Research Site 40972-009
Kfar Saba 294514, , 4428164
Status
Address
Research Site 40972-002
Petah Tikva 293918, , 4941492
Status
Address
Research Site 40972-011
Ramat Gan 293788, , 5262000
Status
Address
Research Site 30060-006
Kampung Kelantan 1768480, ,
Status
Address
Research Site 40052-026
Chihuahua City 4014338, , 31203
Status
Address
Research Site 40052-007
Guadalajara 4005539, , 044100
Status
Address
Research Site 40052-028
Mexico City 3530597, , 06700
Status
Address
Research Site 40052-012
San Juan del Río 3518692, , 76800
Status
Address
Research Site 40048-001
Będzin 3103719, , 42-500
Status
Address
Research Site 40048-018
Bialystok 776069, , 15-044
Status
Address
Research Site 40048-032
Bialystok 776069, , 15-430
Status
Address
Research Site 40048-023
Gdansk 3099434, , 80-214
Status
Address
Research Site 40048-006
Giżycko 772195, , 11-500
Status
Address
Research Site 40048-021
Katowice 3096472, , 40-081
Status
Address
Research Site 40048-002
Katowice 3096472, , 40-365
Status
Address
Research Site 40048-027
Krakow 3094802, , 30-033
Status
Address
Research Site 40048-033
Krakow 3094802, , 31-011
Status
Address
Research Site 40048-008
Krakow 3094802, , 31-159
Status
Address
Research Site 40048-040
Krakow 3094802, , 31-864
Status
Address
Research Site 40048-015
Lodz 3093133, , 90-141
Status
Address
Research Site 40048-009
Lodz 3093133, , 90-302
Status
Address
Research Site 40048-005
Lodz 3093133, , 90-549
Status
Address
Research Site 40048-022
Lublin 765876, , 20-089
Status
Address
Research Site 40048-024
Maków Podhalański 3092517, , 34-220
Status
Address
Research Site 40048-031
Ostrowiec Świętokrzyski 762863, , 27-400
Status
Address
Research Site 40048-010
Piaseczno 762423, , 05-500
Status
Address
Research Site 40048-016
Poznan 3088171, , 61-578
Status
Address
Research Site 40048-039
Rzeszów 759734, , 35-205
Status
Address
Research Site 40048-014
Skierniewice 759123, , 96-100
Status
Address
Research Site 40048-012
Trzebnica 3083103, , 55-100
Status
Address
Research Site 40048-019
Wroclaw 3081368, , 51-162
Status
Address
Research Site 40787-365
Guaynabo 4565119, , 00968
Status
Address
Research Site 40787-390
Ponce 4566880, , 00717
Status
Address
Research Site 40787-388
San Juan 4568127, , 00907
Status
Address
Research Site 40787-383
San Juan 4568127, , 00918
Status
Address
Research Site 40787-405
San Juan 4568127, , 00918
Status
Address
Research Site 40787-360
San Juan 4568127, , 00927
Status
Address
Research Site 40787-345
Vega Baja 4568533, , 00694
Status
Address
Research Site 40040-004
Brasov 683844, Brașov County 683843, 50366
Status
Address
Research Site 40040-006
Cluj-Napoca 681290, Cluj 681291, 400371
Status
Address
Research Site 40040-002
Brasov 683844, , 500051
Status
Address
Research Site 40040-009
Cluj-Napoca 681290, , 400162
Status
Address
Research Site 40040-007
Cluj-Napoca 681290, , 400371
Status
Address
Research Site 40040-001
Constanța 680963, , 900002
Status
Address
Research Site 40040-010
Sângeorgiu de Mureş 667034, , 547365
Status
Address
Research Site 40040-003
Timișoara 665087, , 300310
Status
Address
Research Site 40027-013
Benoni 1020098, , 1500
Status
Address
Research Site 40027-025
Cape Town 3369157, , 7505
Status
Address
Research Site 40027-009
Cape Town 3369157, , 7530
Status
Address
Research Site 40027-011
Cape Town 3369157, , 7570
Status
Address
Research Site 40027-021
Cape Town 3369157, , 7700
Status
Address
Research Site 30090-020
Durban 1007311, , 4001
Status
Address
Research Site 40027-007
Durban 1007311, , 7570
Status
Address
Research Site 40027-026
Johannesburg 993800, , 2193
Status
Address
Research Site 40027-005
KwaZulu 985164, , 4001
Status
Address
Research Site 40027-008
KwaZulu 985164, , 4092
Status
Address
Research Site 40027-020
KwaZulu 985164, , 4170
Status
Address
Research Site 40027-023
KwaZulu 985164, , 4301
Status
Address
Research Site 40027-027
KwaZulu 985164, , 4301
Status
Address
Research Site 40027-010
KwaZulu 985164, , 4450
Status
Address
Research Site 40027-006
Mpumalanga 973111, , 1050
Status
Address
Research Site 40027-004
Pretoria 964137, , 0002
Status
Address
Research Site 40027-019
Pretoria 964137, , 0204
Status
Address
Research Site 40027-018
Vereeniging 944385, , 1935
Status
Address
Research Site 40027-017
Welkom 940909, , 9460
Status
Address
Research Site 40082-003
Anyang-si 1846898, , 14068
Status
Address
Research Site 30082-024
Bucheon-si 1838716, , 14584
Status
Address
Research Site 40082-007
Busan 1838524, , 48108
Status
Address
Research Site 40082-021
Gwangju 1841811, , 61469
Status
Address
Research Site 40082-020
Incheon 1843564, , 21565
Status
Address
Research Site 40082-006
Jeonju 1845457, , 54907
Status
Address
Research Site 40082-019
Seoul 1835848, , 04763
Status
Address
Research Site 40082-012
Seoul 1835848, , 05030
Status
Address
Research Site 40082-008
Seoul 1835848, , 06591
Status
Address
Research Site 40082-004
Seoul 1835848, , 07061
Status
Address
Research Site 40082-011
Seoul 1835848, , 08308
Status
Address
Research Site 40082-010
Suwon 1835553, , 16499
Status
Address
Research Site 40886-001
Kaohsiung City 1673820, , 807
Status
Address
Research Site 40886-004
New Taipei City 12908892, , 220
Status
Address
Research Site 40886-006
New Taipei City 12908892, , 23561
Status
Address
Research Site 40886-005
Taichung 1668399, , 40403
Status
Address
Research Site 40886-007
Taichung 1668399, , 40705
Status
Address
Research Site 40886-010
Taipei 1668341, , 100
Status
Address
Research Site 40886-008
Taipei 1668341, , 110
Status
Address
Research Site 40866-003
Taipei 1668341, , 11217
Status
Address
Research Site 40886-009
Taipei 1668341, , 11240
Status
Address
Research Site 30066-004
Pathum Thani 1607983, , 12120
Status
Address
Research Site 40090-002
Adana 325363, , 01240
Status
Address
Research Site 40090-018
Ankara 323786, , 06230
Status
Address
Research Site 40090-021
Ankara 323786, , 06230
Status
Address
Research Site 40090-024
Ankara 323786, , 06230
Status
Address
Research Site 40090-003
Ankara 323786, , 06560
Status
Address
Research Site 40090-025
Ankara 323786, , 06560
Status
Address
Research Site 40090-008
Ankara 323786, , 06620
Status
Address
Research Site 40090-009
Ankara 323786, , 06930
Status
Address
Research Site 40090-017
Antalya 323777, , 07400
Status
Address
Research Site 40090-019
Bornova 320857, , 35100
Status
Address
Research Site 40090-020
Istanbul 745044, , 34020
Status
Address
Research Site 40090-026
Istanbul 745044, , 34750
Status
Address
Research Site 40090-011
Istanbul 745044, , 34844
Status
Address
Research Site 40090-012
Konak 308969, , 35110
Status
Address
Research Site 40090-016
Merkez 388147, , 17020
Status
Address
Research Site 40090-013
Mersin 304531, , 33110
Status
Address
Research Site 40090-024
Pendik 740616, ,
Status
Address
Research Site 40090-022
Tekirdağ 738927, , 59100
Status
Address
Research Site 40380-002
Chernivtsi 710719, , 58001
Status
Address
Research Site 40380-021
Chernivtsi 710719, , 58022
Status
Address
Research Site 40380-009
Ivano-Frankivsk 707471, , 76008
Status
Address
Research Site 40380-004
Ivano-Frankivsk 707471, , 76018
Status
Address
Research Site 40380-017
Ivano-Frankivsk 707471, , 76018
Status
Address
Research Site 40380-014
Ivano-Frankivsk 707471, , 76019
Status
Address
Research Site 40380-019
Kyiv 703448, , 02002
Status
Address
Research Site 40380-018
Kyiv 703448, , 03037
Status
Address
Research Site 40380-007
Kyiv 703448, , 03038
Status
Address
Research Site 40380-010
Kyiv 703448, , 03038
Status
Address
Research Site 40380-012
Kyiv 703448, , 03038
Status
Address
Research Site 40380-015
Kyiv 703448, , 03049
Status
Address
Research Site 40380-011
Kyiv 703448, , 03057
Status
Address
Research Site 40380-013
Kyiv 703448, , 03115
Status
Address
Research Site 40380-016
Lutsk 702569, , 45634
Status
Address
Research Site 40380-001
Ternopil 691650, , 46023
Status
Address
Research Site 40380-003
Vinnytsia 689558, , 21001
Status
Address
Research Site 40380-020
Vinnytsia 689558, , 21018
Status
Address
Research Site 40380-008
Vinnytsia 689558, , 21029
Status
Address
Research Site 40380-022
Vinnytsia 689558, , 21029
Status
Address
Research Site 40380-005
Zhytomyr 686967, , 10002
Status
Address
Research Site 40044-018
Bellshill 2655952, , ML4 3NJ
Status
Address
Research Site 40044-021
Birmingham 2655603, , B15 2SQ
Status
Address
Research Site 40044-077
Bollington 2655245, , SK10 5JH
Status
Address
Research Site 40044-017
Chorley 2653086, , PR7 7NA
Status
Address
Research Site 40044-022
Enfield 2649997, , EN3 4GS
Status
Address
Research Site 40044-019
Liverpool 2644210, , L22 0LG
Status
Address
Research Site 40044-084
London 2643743, , E1 1 EQ
Status
Address
Research Site 40044-001
Manchester 2643123, , BL9 0NJ
Status
Address
Research Site 40044-020
Manchester 2643123, , M15 6SE
Status
Address
Research Site 40044-013
Manchester 2643123, , M22 4DH
Status
Address
Research Site 40044-009
Manchester 2643123, , M24 4DZ
Status
Address
Research Site 40044-036
Manchester 2643123, , M27 0EW
Status
Address
Research Site 40044-006
Manchester 2643123, , M33 4BR
Status
Address
Research Site 40044-024
Preston 2639912, , PR2 9RB
Status
Address
Research Site 40044-026
Rochdale 2639272, , OL11 4AU
Status
Address
Research Site 40044-008
Salford 2638671, , M6 5WW
Status
Address
Research Site 40044-034
Stockport 2636882, , SK8 5LL
Status
Address
Research Site 40044-078
Wythenshawe 2633432, , M23 9QZ
